Efficacy of dorzolamide-timolol combination as an adjunct to Intravitreal Bevacizumab in treatment of macular edema due to retinal vein occlusion
Abstract
AIM -To study the effect of a topical aqueous suppressant in treatment of macular edema in branch retinal vein occlusion (BRVO).MATERIALS AND METHODS - In this study, two groups of 20 patients each with macular edema due to BRVO were randomized to receive IVB (2.5mg0.1ml) laser dorzolamide-timolol combination thrice daily (study group) or IVB laser (control group). Main outcome measures studied were visual acuity, reduction in central foveal thickness (CFT) and recurrence of macular edema. RESULTS -There was no significant difference between the 2 groups at 1 month but eyes in the control group had a significantly higher CFT at 6 months (p0.01) than study eyes. Visual acuity at 6 months was also better in study eyes than control eyes but this difference was not significant. CONCLUSION -Topical dorzolamide-timolol given thrice daily prolongs the effect of IVB thereby reducing the frequency of recurrence of macular edema in eyes with BRVO.
Full Text:
PDFReferences
Noergaard et al. Dorzolamide increases retinal oxygen tension after BRVO. Invest Ophthalmol. Vis. Sci. 2008 March;49(3):1136-41
Wolfensberger. The Role of Carbonic anhydrase inhibitors in the management of macular edema. Doc. Ophthalmologica. 1999;97 (3-4):387-97
Byeon et al. Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant. Graefes Arch.Clin.Exp .Ophthalmol. 2009 Jan;247(1)35-42
Lattanzio et al . Retinal vein occlusion- current treatment 2011; Ophthalmologica
The SCORE study Archives of ophthalmology. Sep. 2009
Kreutzer et al. Intravitreal bevacizumab for the treatment of macular edema secondary to BRVO. Br.J.Ophthalmol.2008;92:351-355
Kriechbaum et al. Intravitreal Avastin for macular edema secondary to RVO. Br.J.Ophthalmol.2008;92:518-252
Schaal et al. Bevacizumab for the treatment of macular edema secondary to RVO. Ophthalmologe 2007; 104: 285-289
Deka et al. Rebound effect following intravitreal bevacizumab in BRVO. Oman J. Ophthalmology 2009 may-Aug; 2 (2): 94-95.
Jaissle et al. Bevacizumab for treatment of macular edema secondary to RVO. Ophthalmologe.2006; 103:471-75
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An Initiative of The Tamil Nadu Dr MGR Medical University